CritiTech Consolidates R&D and Commercial Operations

July 26, 2005

LAWRENCE, Kan.- CritiTech, Inc., announced that it has completed the transfer of its technology and R&D laboratory operations from the Higuchi Biosciences Center at the University of Kansas to its new facility located in the West Lawrence Laboratories at 4950 Research Park Way, Lawrence, Kansas. The commercial operation of the company was established at 4950 Research Park Way in mid year 2004. The addition of Jahna Howell as Director of Laboratory Operations has enabled the company to consolidate its R&D and commercial activity into a single location and to expand its in-house drug development program. Dr. Charles Decedue, Executive Director of the Higuchi Biosciences Center and the Chairman of the CritiTech Scientific Advisory Board, stated “we are pleased to see CrtiTech’s continued growth to the operational phase of their business plan and proud to have been a part of that growth and development. We are confident that the addition of Jahna Howell will complete the transfer of supercritical fluid, nanoparticle technology from the Higuchi Biosciences Center to CritiTech. Equally, we look forward to future work with CritiTech as a corporate partner in future drug development projects.”

CritiTech provides critical drug delivery and development technology for the pharmaceutical industry through its patented nanoparticle production technology originally developed at the University of Kansas. In addition, the company uses its proprietary technology to coat implantable medical devices such as cardiac stents. This enables devices to be implanted with less concern about restenosis and rejection.

Contact: Sam Campbell, CritiTech CEO and president, (785) 841-7120